Archive for the ‘faked data’ Category
A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).
Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:
Last week, we reported that PLoS ONE was retracting three papers by the research group because “there are no data available underlying this study and thus…the published results are fabricated.” Now, according to The Hindu, four more papers are being retracted:
Read the rest of this entry »
The article, “Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study,” purported to show that: Read the rest of this entry »
This one comes to us from Twitter, where Willem van Schaik went to express his frustration that a PLOS ONE paper he’d edited had been retracted for fake data.
Two other papers from the same group at the Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India, were retracted simultaneously.
We sent van Schaik an email to get a clearer picture of the situation. He responded: Read the rest of this entry »
CrossFit to be tied: Fitness company sues journal to retract “sloppy and scientifically unreliable work”
Lawsuits are usually dry and boring, so it’s always fun to read one with a little life.
Here’s one of those: CrossFit, the fitness program famous for its brief, strenuous exercises and passionate devotees, is suing the National Strength and Conditioning Association (NCSA), which it considers its staid competitor for the nation’s sweat and cash.
According to CrossFit, the NSCA published a study with a “falsified rate of injury,” “in an effort to portray CrossFit as ‘dangerous’ and therefore a fitness program that should be avoided.”
No matter that the study, published in NSCA’s official research journal, the Journal of Strength and Conditioning Research, concluded overall that CrossFit is a useful form of exercise. The suit says that the authors fudged a few statistics about participants’ injuries. Here’s the relevant section from the paper, titled “Crossfit-based high-intensity power training improves maximal aerobic fitness and body composition:”
A Boston doctor indicted on charges of Medicare fraud in 2007 has had a paper relating to the case retracted this month.
Abdul Razzaque Ahmed was considered something of a miracle worker by his patients, treating two rare and disfiguring skin conditions called pemphigoid and pemphigus vulgaris. He used more powerful medicines than the typical course of treatment, including a drug normally used to treat cancer.
The initial indictment stated that Ahmed mixed blood samples to falsely show a “dual diagnosis” of both diseases, and prove to Medicare that they required the more rigorous (and expensive) treatment. It also alleged that he profited massively from the government pay-outs. He was convicted of obstruction in 2007; the other charges were dropped when he agreed to forfeit assets worth $2.9 million.
Now, a 2001 paper by Ahmed, which claimed fifteen patients had a dual diagnosis, has been retracted because the samples were all mixed. Here is the retraction notice from Clinical Immunology: Read the rest of this entry »
Melanie Pallansch-Cokonis, a former research technician at Southern Research Institute, faked data in work funded by NIH contracts and grants, according to the Office of Research Integrity (ORI).
Karel Bezouška, the scientist who tried to derail an investigation into his work by breaking into a lab refrigerator has had an eighth paper retracted.
Here’s the notice for “Synthetic N-Acetyl-d-glucosamine Based Fully Branched Tetrasaccharide, a Mimetic of the Endogenous Ligand for CD69, Activates CD69+ Killer Lymphocytes upon Dimerization via a Hydrophilic Flexible Linker:” Read the rest of this entry »